Tema Oncology ETF (NASDAQ:CANC) Short Interest Update
by Sarita Garza · The Markets DailyTema Oncology ETF (NASDAQ:CANC – Get Free Report) was the recipient of a significant increase in short interest during the month of August. As of August 31st, there was short interest totaling 22,352 shares, an increase of 108.9% from the August 15th total of 10,698 shares. Currently, 0.5% of the company’s stock are short sold. Based on an average daily volume of 22,950 shares, the days-to-cover ratio is presently 1.0 days.
Institutional Trading of Tema Oncology ETF
Several hedge funds have recently made changes to their positions in CANC. Jane Street Group LLC acquired a new stake in shares of Tema Oncology ETF in the 1st quarter valued at approximately $213,000. Flow Traders U.S. LLC purchased a new stake in Tema Oncology ETF during the 3rd quarter worth about $630,000. Thrivent Financial for Lutherans raised its position in shares of Tema Oncology ETF by 891.1% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,461,649 shares of the company’s stock valued at $50,747,000 after buying an additional 1,314,177 shares during the last quarter. LPL Financial LLC acquired a new position in Tema Oncology ETF in the 4th quarter valued at $278,000. Finally, Roxbury Financial LLC purchased a new position in Tema Oncology ETF during the first quarter worth about $34,000.
Tema Oncology ETF Stock Up 1.4%
NASDAQ:CANC traded up $0.58 during mid-day trading on Monday, reaching $42.11. 11,475 shares of the stock were exchanged, compared to its average volume of 31,157. The stock has a market capitalization of $200.87 million, a P/E ratio of 20.39 and a beta of 0.69. Tema Oncology ETF has a 1 year low of $26.62 and a 1 year high of $47.00. The company has a 50 day simple moving average of $42.47 and a 200-day simple moving average of $39.32.
About Tema Oncology ETF
The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.